ArticleDiabetes2009
Amylase alpha-2A autoantibodies: novel marker of autoimmune pancreatitis and fulminant type 1 diabetes.
Article in Diabetes, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed, 119 citations in OpenAlex.
- Smoking, alcohol consumption, and new-onset impaired glucose metabolism in male patients with type 1 autoimmune pancreatitis: a retrospective cohort study.Therapeutic advances in chronic disease · 2025Article
- Scars of oxidative stress: protein carbonylation and beta cell dysfunction in diabetes.Frontiers in endocrinology · 2025Review
- Current and future advances in practice: IgG4-related disease.Rheumatology advances in practice · 2024Review
- IgG4 Antibodies Induced by Repeated Vaccination May Generate Immune Tolerance to the SARS-CoV-2 Spike Protein.Vaccines · 2023Review
- Serum biomarkers for the differentiation of autoimmune pancreatitis from pancreatic ductal adenocarcinoma.World journal of gastrointestinal oncology · 2023Review
- Type 1 Diabetes: A Disorder of the Exocrine and Endocrine Pancreas.Journal of cellular immunology · 2023Article
- The spectrum of B cells in the pathogenesis, diagnosis and therapeutic applications of immunoglobulin G4-related disease.Clinical & translational immunology · 2023Review
- Review
- Carbonyl Posttranslational Modification Associated With Early-Onset Type 1 Diabetes Autoimmunity.Diabetes · 2022Article
- The Clinical Utility of Soluble Serum Biomarkers in Autoimmune Pancreatitis: A Systematic Review.Biomedicines · 2022Review
- Neutralizing anti-IL-1 receptor antagonist autoantibodies induce inflammatory and fibrotic mediators in IgG4-related disease.The Journal of allergy and clinical immunology · 2022Article
- Biomarkers of autoimmunity and beta cell metabolism in type 1 diabetes.Frontiers in immunology · 2022Review
- Histological features of autoimmune pancreatitis and IgG4-related sclerosing cholangitis with a correlation with imaging findings.Journal of medical ultrasonics (2001) · 2021Review
- Diabetes mellitus induced by immune checkpoint inhibitors: type 1 diabetes variant or new clinical entity? Review of the literature.Reviews in endocrine & metabolic disorders · 2021Review
- Review of Diagnostic Biomarkers in Autoimmune Pancreatitis: Where Are We Now?Diagnostics (Basel, Switzerland) · 2021Review
- IgG4-related disease: an update on pathophysiology and implications for clinical care.Nature reviews. Rheumatology · 2020Review
- Exocrine Pancreas Dysfunction in Type 1 Diabetes.Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists · 2020Review
- Unique pathological changes in the pancreas of fulminant type 1 diabetes.Diabetology international · 2020Review
- Review
- IgG4-related pancreatitis: an uncommon cause of hyperglycaemia.BMJ case reports · 2020Article
Corrections and comments
- Commented on by
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe pathogenesis of autoimmune pancreatitis (AIP) and fulminant type 1 diabetes remains unclear, although it is known that immune-mediated processes severely compromise the endocrine and exocrine functions in both diseases. RESEARCH DESIGN AND
methodsWe have screened a lambdaTriplEx2 human pancreas cDNA library with serum from a patient with AIP and obtained positive clones. Sequence analysis revealed that 7 of 10 clones were identical to human amylase alpha-2A. Using a recombinant COOH-terminal amylase alpha-2A protein, we developed an enzyme-linked immunosorbent assay system to detect autoantibodies against human amylase alpha-2A.
resultsAll 15 serum samples from patients with AIP recognized the recombinant protein, whereas sera from 25 patients with chronic alcoholic pancreatitis and sera from 25 patients with a pancreas tumor did not. Interestingly, 88% (15/17) of patients with fulminant type 1 diabetes were positive for an autoantibody against amylase alpha-2A. These antibodies were detected in 21% of patients with acute-onset type 1 diabetes (9 of 42) and 6% of type 2 diabetic patients (4 of 67).
conclusionsThese results suggest that an autoantibody against amylase alpha-2A is a novel diagnostic marker for both AIP and fulminant type 1 diabetes and that, clinically and immunologically, AIP and fulminant type 1 diabetes are closely related.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.